NCT02206464View on ClinicalTrials.gov

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 29, 2014

Primary Completion Date

January 7, 2016

Study Completion Date

January 7, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

A/Shanghai/02/2013 (H7N9) MIV

Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)

BIOLOGICAL

VRC-FLUDNA071-00-VP

H7 DNA Vaccine

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02206464 - H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo... | Biotech Hunter | Biotech Hunter